Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.

South Korea designates two more global innovative products for support under a new fast track system, in a move set to speed up patient access to novel therapies.

Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.

Having previously an agreement with BioFactura to assess the company’s proposed ustekinumab biosimilar with its RaniPill oral drug delivery technology, Rani has now unveiled a deal with Korean major Celltrion for use of its CT-P43 Stelara biosimilar candidate.